Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL
暂无分享,去创建一个
H. Dombret | E. Macintyre | S. Spicuglia | S. Leprêtre | X. Thomas | N. Ifrah | F. Pflumio | D. Puthier | V. Asnafi | N. Boissel | M. Belhocine | C. Graux | Y. Chalandon | M. Hunault | F. Huguet | E. Lengliné | T. Leguay | Charlotte Smith | A. Touzart | M. Latiri | Mohamed Belhocine
[1] G. Salles,et al. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Dombret,et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[3] F. Speleman,et al. Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia , 2015, Leukemia.
[4] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[5] Stein Aerts,et al. Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia , 2013, PLoS genetics.
[6] B. Nadel,et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] I. Heřmanová,et al. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. , 2012, Experimental hematology.
[8] B. Nadel,et al. TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression. , 2012, Cancer cell.
[9] Andrew P. Stubbs,et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.
[10] S. Spicuglia,et al. Assessing the efficiency and significance of Methylated DNA Immunoprecipitation (MeDIP) assays in using in vitro methylated genomic DNA , 2010, BMC Research Notes.
[11] O. Haas,et al. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T‐cell acute lymphoblastic leukaemia treated with Berlin–Frankfurt–Münster (BFM) protocols containing early and late re‐intensification elements , 2010, British journal of haematology.
[12] H. Dombret,et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.
[13] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Denis Thieffry,et al. CoCAS: a ChIP-on-chip analysis suite , 2009, Bioinform..
[15] E. Thiel,et al. Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group , 2008, Leukemia.
[16] S. Hunger,et al. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines , 2008, Pediatric blood & cancer.
[17] J. Meijerink,et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences , 2008, Leukemia.
[18] J. Soulier,et al. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. , 2007, Blood.
[19] J. Downing,et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. , 2007, The Journal of clinical investigation.
[20] D. Neuberg,et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.
[21] W. Kamps,et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. , 2006, Haematologica.
[22] W. Kamps,et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Sather,et al. Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on Children's Cancer Group protocols , 2005, Leukemia.
[24] Hong Chen,et al. Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. , 2005, Annual review of nutrition.
[25] F. Sigaux,et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). , 2005, Blood.
[26] W. Evans,et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. , 2005, Blood.
[27] M. D. Boer,et al. Upregulation of asparagine synthetase and cell cycle arrest in t(12;21)-positive ALL , 2005, Leukemia.
[28] L. Boxer,et al. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. , 2005, Cancer research.
[29] Yuan-Xiang Pan,et al. Amino Acid Deprivation Induces the Transcription Rate of the Human Asparagine Synthetase Gene through a Timed Program of Expression and Promoter Binding of Nutrient-responsive Basic Region/Leucine Zipper Transcription Factors as Well as Localized Histone Acetylation* , 2004, Journal of Biological Chemistry.
[30] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[32] M. Caligiuri,et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia , 2004, The Lancet.
[33] F. Speleman,et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. , 2004, Blood.
[34] N. Heerema,et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG) , 2003, Leukemia.
[35] M. D. Den Boer,et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. , 2003, Blood.
[36] P. Lutz,et al. High incidence of Hox11L2 expression in children with T-ALL , 2002, Leukemia.
[37] J. Zucman‐Rossi,et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. , 2002, Blood.
[38] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[39] M. Kilberg,et al. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. , 2001, The Biochemical journal.
[40] R. Gelber,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.
[41] J. Shuster,et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. , 2000, Blood.
[42] S. Korsmeyer,et al. Rnx deficiency results in congenital central hypoventilation , 2000, Nature Genetics.
[43] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[44] M. Amylon,et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.
[45] S. Schuster,et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. , 1997, The American journal of physiology.
[46] S. Korsmeyer,et al. Hox11 controls the genesis of the spleen , 1994, Nature.
[47] R. Gelber,et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. , 1983, Cancer research.
[48] C. Haskell,et al. l-asparaginase resistance in human leukemia--asparagine synthetase. , 1969, Biochemical pharmacology.
[49] M. Baliś,et al. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. , 1969, Cancer research.